IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses

Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recogni...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	International journal of molecular sciences Ročník 22; číslo 21; s. 11848
Hlavní autoři:	Harper, Taylor A., Bacot, Silvia M., Fennell, Christie Jane, Matthews, Rebecca L., Zhu, Christina, Yue, Peng, Benton, Alexander, Friedman, Devira, Akue, Adovi, KuKuruga, Mark A., Lee, Shiowjen, Wang, Tao, Feldman, Gerald M.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland MDPI AG 31.10.2021 MDPI
Témata:	Apoptosis Cancer Clinical trials Cytokines FDA approval Humans Immunotherapy Interferon-gamma - immunology Interleukin-10 - immunology Interleukin-2 Receptor alpha Subunit - immunology Ki-67 Antigen - immunology Lymphocyte Activation - drug effects Lymphocytes MAP Kinase Signaling System - drug effects MAP Kinase Signaling System - immunology Melanoma Nivolumab - pharmacology T-Lymphocytes - immunology Targeted cancer therapy STAT3 pathway nivolumab AKT serine–threonine kinase pathway MAP kinase pathway cytokines T cells interleukin 10
ISSN:	1422-0067, 1661-6596, 1422-0067
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!